Page 133 - 2022-24-中国全科医学
P. 133

·3074· http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn


           ［6］SCHORRY E K，KEDDACHE M，LANPHEAR N，et al. Genotype-  ［18］PARK E，KIM Y，RYU H，et al. Epigenetic mechanisms of
               phenotype correlations in Rubinstein-Taybi syndrome［J］.   Rubinstein-Taybi syndrome［J］. Neuromolecular Med，2014，16
               Am J Med Genet A，2008，146A（19）：2512-2519. DOI：       （1）：16-24. DOI：10.1007/s12017-013-8285-3.
               10.1002/ajmg.a.32424.                           ［19］BEDFORD D C，BRINDLE P K. Is histone acetylation the most
           ［7］BENTIVEGNA  A，MILANI  D，GERVASINI  C，et  al.          important physiological function for CBP and p300? ［J］. Aging，
               Rubinstein-Taybi Syndrome：spectrum of CREBBP mutations in   2012，4（4）：247-255. DOI：10.18632/aging.100453.
               Italian patients［J］. BMC Med Genet，2006，7：77. DOI：  ［20］KORZUS  E.  Rubinstein-Taybi  syndrome  and  epigenetic
               10.1186/1471-2350-7-77.                              alterations［J］. Adv Exp Med Biol，2017，978：39-62. DOI：
           ［8］WINCENT J，LUTHMAN A，VAN BELZEN M，et al. CREBBP        10.1007/978-3-319-53889-1_3.
               and EP300 mutational spectrum and clinical presentations in a cohort   ［21］ALARI V，RUSSO S，TERRAGNI B，et al. iPSC-derived neurons
               of Swedish patients with Rubinstein-Taybi syndrome［J］. Mol Genet   of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome
               Genomic Med，2015，4（1）：39-45. DOI：10.1002/mgg3.177.   patients show morphological alterations and hypoexcitability［J］.
           ［9］NEGRI G，MILANI D，COLAPIETRO P，et al. Clinical and     Stem  Cell  Res，2018，30：130-140.  DOI：10.1016/j.
               molecular characterization of Rubinstein-Taybi syndrome patients   scr.2018.05.019.
               carrying distinct novel mutations of the EP300 gene［J］. Clin   ［22］CALZARI L，BARCELLA M，ALARI V，et al. Transcriptome
               Genet，2015，87（2）：148-154. DOI：10.1111/cge.12348.     analysis of iPSC-derived neurons from Rubinstein-Taybi patients
           ［10］BARTHOLDI  D，ROELFSEMA  J  H，PAPADIA  F，et  al.      reveals deficits in neuronal differentiation［J］. Mol Neurobiol，
               Genetic heterogeneity in Rubinstein-Taybi syndrome：delineation   2020，57（9）：3685-3701. DOI：10.1007/s12035-020-
               of the phenotype of the first patients carrying mutations in   01983-6.
               EP300［J］. J Med Genet，2007，44（5）：327-333. DOI：  ［23］ALARI  V，SCALMANI  P，AJMONE  P  F，et  al.  Histone
               10.1136/jmg.2006.046698.                             deacetylase inhibitors ameliorate morphological defects and
           ［11］NEGRI G，MAGINI P，MILANI D，et al. From whole gene     hypoexcitability  of  iPSC-neurons  from  Rubinstein-Taybi
               deletion to point mutations of EP300-positive Rubinstein-Taybi   patients［J］. Int J Mol Sci，2021，22（11）：5777. DOI：
               patients：new insights into the mutational spectrum and peculiar   10.3390/ijms22115777.
               clinical hallmarks［J］. Hum Mutat，2016，37（2）：175-183.   ［24］DI FEDE E，OTTAVIANO E，GRAZIOLI P，et al. Insights
               DOI：10.1002/humu.22922.                              into the role of the microbiota and of short-chain fatty acids in
           ［12］SPENA S，GERVASINI C，MILANI D. Ultra-rare syndromes：  Rubinstein-Taybi syndrome［J］. Int J Mol Sci，2021，22（7）：
               the example of Rubinstein-Taybi syndrome［J］. J Pediatr Genet，  3621. DOI：10.3390/ijms22073621.
               2015，4（3）：177-186. DOI：10.1055/s-0035-1564571.  ［25］BABU A，KAMARAJ M，BASU M，et al. Chemical and genetic
           ［13］RUSCONI D，NEGRI G，COLAPIETRO P，et al. Characterization   rescue of an ep300 knockdown model for Rubinstein Taybi Syndrome
               of 14 novel deletions underlying Rubinstein-Taybi syndrome：  in zebrafish［J］. Biochim Biophys Acta Mol Basis Dis，2018，1864（4
               an update of the CREBBP deletion repertoire［J］. Hum Genet，  Pt A）：1203-1215. DOI：10.1016/j.bbadis.2018.01.029.
               2015，134（6）：613-626. DOI：10.1007/s00439-015-1542-9.   ［26］CROSS E，DUNCAN-FLAVELL P J，HOWARTH R J，et al.
           ［14］FERGELOT P，VAN BELZEN M，VAN GILS J，et al. Phenotype   Screening of a large Rubinstein-Taybi cohort identified many novel
               and genotype in 52 patients with Rubinstein-Taybi syndrome caused   variants and emphasizes the importance of the CREBBP histone
               by EP300 mutations［J］. Am J Med Genet A，2016，170（12）：  acetyltransferase domain［J］. Am J Med Genet A，2020，182（11）：
               3069-3082. DOI：10.1002/ajmg.a.37940.                 2508-2520. DOI：10.1002/ajmg.a.61813.
           ［15］RAMOS Y F，HESTAND M S，VERLAAN M，et al. Genome-  ［27］PÉREZ-GRIJALBA V，GARCÍA-OGUIZA A，LÓPEZ M，et al.
               wide  assessment  of  differential  roles  for  p300  and  CBP  in   New insights into genetic variant spectrum and genotype-phenotype
               transcription regulation［J］. Nucleic Acids Res，2010，38（16）：  correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive
               5396-5408. DOI：10.1093/nar/gkq184.                   patients［J］. Mol Genet Genomic Med，2019，7（11）：e972.
           ［16］LIPINSKI M，DEL BLANCO B，BARCO A. CBP/p300 in brain   DOI：10.1002/mgg3.972.
               development and plasticity：disentangling the KAT's cradle［J］.   ［28］SPENA S，MILANI D，RUSCONI D，et al. Insights into genotype-
               Curr  Opin  Neurobiol，2019，59：1-8.  DOI：10.1016/j.   phenotype correlations from CREBBP point mutation screening
               conb.2019.01.023.                                    in a cohort of 46 Rubinstein-Taybi syndrome patients［J］. Clin
           ［17］KALKHOVEN E. CBP and p300：hats for different occasions［J］.   Genet，2015，88（5）：431-440. DOI：10.1111/cge.12537.
               Biochem  Pharmacol，2004，68（6）：1145-1155.  DOI：             （收稿日期：2022-03-04；修回日期：2022-05-16）
               10.1016/j.bcp.2004.03.045.                                                        （本文编辑：程圣）
   128   129   130   131   132   133